CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.
CancerNetwork® sat down with Ronnie Shapira-Frommer, MD, to discuss the antitumor activity of pembrolizumab monotherapy in a cohort of patients with previously treated vulvar squamous cell carcinoma from the phase 2 KEYNOTE-158 trial (NCT02628067).
In a presentation at the Society of Gynecological Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer, Shapira-Frommer presented data showing objective responses were achievable in this patient subgroup with the PD-1 inhibitor.
One hundred and one patients [with vulvar squamous cell carcinoma] were treated on the study and 11% responded to the treatment (10.9%); 1 had a complete response and 10 had partial responses. Among these responding patients, median duration of response was 20 months. Indeed, [there was a] low percentage of response, but [there were] significant and meaningful responses for some of these patients.
Interestingly, response was irrespective of PD-L1 expression, unlike in cervical cancer, so patients could respond whether they had a PD-L1–positive tumor [or] PD-L1–negative expression. As we could see, some of the responses were very durable and therefore meaningful.
Frommer RS, Mileshkin L, Manzyuk L, et al. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study. Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19-21, 2021; Virtual. Abstract 11603.